One overlooked American biotech just made your immune system 1,000 times more effective...

Here's how it could make your portfolio 1,000 times healthier

Dear Reader,

http://www.angelnexus.com/o/web/54788?r=1

AND ALSO AT http://www.wealthdaily.com/reports/ebook-21810.pdf

Deaths from earthquakes, wars, hurricanes, tsunamis, terrorism, and genocide grab all the headlines...
But disease is perennially the world's #1 killer — by hundreds of times over.
That's why it rarely makes headlines. Death from disease is simply too commonplace to be considered "newsworthy."
In the United States alone, the yearly body count is frightening — to the point of near disbelief:

Lung Cancer: 159,480 deaths
Prostate Cancer: 29,720 deaths
Colon/Rectal Cancer: 50,830 deaths
Breast Cancer: 39,610 deaths
Bladder Cancer: 15,210 deaths
Ovarian Cancer: 14,600 deaths
Hepatitis C: 15,000 deaths
Influenza: 50,497 deaths
HIV: 15,529 deaths

That's approximately 400,000 Americans killed every year from just nine major diseases... more than 50 times the U.S. combat death count from the Iraq and Afghanistan Wars combined.

Imagine what the body count must be worldwide...

If the U.S. loses 400,000 people a year amidst the world's most advanced, highest-tech health care system, the rest of the globe must lose tens of millions of people to these diseases.

What if I told you that one miniscule, all-but-ignored American bio-pharma firm owns the breakthrough that could soon render all these millions of deaths a thing of the past?

What if I told you that this company is already seeing success on human subjects using this technology that turns the genes of viruses and cancerous cells against themselves...

And what if I said that right now, you have a brief window of opportunity to scoop up shares of this destined-to-change-the-world company for less than $3.00 apiece?

That's the kind of once-in-your-life profit play that could conceivably turn every dollar you invest into $100 at least — and maybe $1,000 or more.

Don't believe me?
I'll prove it to you right now...

How You Could've Banked More than 2,000% Gains on "Breakthrough" Drugs that Save
No More than 7,000 Americans a Year

Human Genome Sciences (HGS) was another micro-biotech firm that perfected a one-of-a-kind drug mechanism that cured the deadly disease Lupus.

Not to downplay the impact of this painful autoimmune condition, but the truth is Lupus is not very common. It affects only .53% of Americans, and it is highly survivable.

In fact, on average, fewer than 1,500 people died in the United States from Lupus each year before HGS's miraculous drug hit the market.

Nevertheless, when the news of their breakthrough's success in treating the disease came out, the company's stock shot up 276% in three days...

And in less than six months, it was up over 1,060%:

Human Genome Sciences was eventually bought out by GlaxoSmithKline in 2012, sending shares up 80% in just a month.

Cancer, as I'm sure you're aware, is thousands of times more prevalent than Lupus.

Most of us have had the unfortunate experience of having or knowing someone who has had some form of cancer...

Take a look at the 1,049% gains that micro-pharma Dendreon (DNDN) paid shareholders in the few short months following news of their "breakthrough" — a drug that cut the death rate from prostate cancer by just 20% (that translates to around 5,500 lives per year):

See how dramatic the gains of these under-the-radar biotechs can be?

Breakthroughs in the treatment of low-mortality diseases — or for advancements that merely chip away at the death tolls of major diseases — can routinely pay a fast 10 times your money.

But can you imagine what would happen to your bottom line if you owned shares of a company with the superior drug technology that gave hope to hundreds of millions of virus and cancer sufferers?

The increase in their share prices would easily make the more than 2,000% gains you could have made on these micro-biotechs HGS and DNDN look like pennies at the bottom of a bucket.

Seriously, think about what an ignored micro-pharma with the key to defeating almost every major killer disease on the planet — cancers, malarias, influenzas, HIV, and others — could pay you...

It would be no stretch at all to count on 100x returns on your investment.

And as I'll prove to you shortly, 1,000 times your money would not be out of the realm of possibility...

But only if you stocked up on shares while they were dirt cheap and ignored.

Wait too long on an opportunity like this, and everyone else will be counting your money.

So by now, surely you're dying to know: What's this technology that's going to revolutionize how we treat the world's deadliest diseases?

Well, let me start by showing you how effective it is against just ONE killer disease that terrorized the world not so long ago...

How This Breakthrough Biotechnology Could've Saved Over 50 Million People in One Year

In 1918, a killer "Spanish Flu" pandemic terrorized the planet, infecting one-third of the world's population in one of the worst disease outbreaks in modern history.

And every year, one of the 13 strains of the flu threatens to break its restraints and evolve into a form as deadly as the 1918 strain.

But that's about to be a thing of the past.

If the results of the initial live trials hold true, then we can say that there now exists a technology that already has proven to be 100% effective against the strain that started this deadly plague.

In 1918, that would have meant over 50 million spared lives.

How could one drug have prevented all these deaths?

By combining two little-known and under-utilized technologies perfected by the revolutionary micro-biotech firm that I'll reveal to you shortly:

A type of vaccine known as a "Genetic Vaccine"
A delivery system that makes that particular vaccine 1,000 times more effective in initiating an immune response

You see, viruses normally rely on molecular "lock picks" to get access into our own cells and then replicate. Our body's protection requires the production of antibodies, which either bolster our cellular "locks" to prevent the virus from entering into our cells, or mark these viruses for destruction by our white blood cells.

This is also how traditional vaccines have worked for the past 80 years...

They use dead virus strains to trick our immune system into developing antibodies so that they're prepared for an infection in the case one happens.

And while our immune system and vaccines are pretty amazing at defending our bodies from invaders, cancer cells and viruses are equally adept at eluding these bulwarks:

Cancer cells, being simply mutated versions of our normal cells, are able to replicate beyond control because the body still recognizes them as its own, even though they now have different genes.
Viruses replicate so fast and so often that they are able to change their "keys" at an unnerving speed, quickly rendering any immunity to that virus ineffective.

The virus' ability to, in effect, change their molecular lock picks has enabled them to always be one step ahead of the vaccine industry — which is why we have to get a different flu vaccine each year.

"In 21st century America, we are waging war on a lethal infectious disease
with World War I-era technology."

— Washington Times

This highlights perhaps the biggest problem with our current vaccine technology: It can never be 100% effective.

But that's not the only problem with our current vaccine production methods...

Traditional vaccines rely on pumping chicken eggs with viruses and waiting until they die to harvest and purify them, which means our vaccine supplies must rely on the instability of the egg market.
This process can take up to six months, which often provides vaccines too late for a seasonal epidemic like the flu.
Relying on a live vaccine opens up the body to a multitude of side effects, not to mention the cost of extra protection measures during development needed for worker and public safety.

This may have flown during the 20^th century, but with new and more virulent diseases emerging at an exponential rate... and cancer still relying on painful radiation and chemotherapy treatments that are never 100% effective.

"At least 45 diseases that have passed from animals to humans have been reported to UN agencies in the last two decades, with the number expected to escalate in the coming years."

— Independent (UK)

I think we can all agree that a vaccine to take care of all the major viral and infectious diseases is long overdue...

Which is where the breakthrough company I'm about to reveal comes in.

While they've kept themselves under the radar, our featured micro-biotech firm is also not new to the vaccine scene.

They've been developing this particular technology for the past 16 years.

In just a moment, I'm going to tell you all about how you could take advantage of this company's futuristic advancements to make those 100x-1,000x gains I was telling you about earlier.

But first, let me tell you a little more about the technology that is also on its way to...

Bring Investors 10,000% Returns by Destroying the Cancer Epidemic

Remember how I was telling you what keeps viruses coming back year after year is their ability to keep eluding our defenses by changing the picks to our bodies' cells?

Well, you can now consider that little viral trick a thing of the past...

Because our firm's unique genetic vaccines utilize the virus' own DNA, which is genetically altered and then injected into cells to produce antibodies that are not fooled by the virus' change in picks.

And this is just the beginning.

Because DNA is easily replicated in laboratory settings, the vaccine does not need to rely on chicken eggs to incubate the virus...
Which not only means they have a more reliable source for the vaccine, but the turn-around time for its production is now a mere two to three weeks!
Moreover, this type of vaccine — because it doesn't rely on a live virus — can be shipped and stored in a variety of conditions...
Including those areas in developing countries that have difficulty storing traditional vaccines due to lack of refrigeration.

Add to this the ridiculously cheap cost of manufacturing genetic vaccines, and you have some great news for an industry already worth over $22.5 billion.

It's also good news for those investors who've already started to ride this company's technological potential.

The flu vaccine market alone pulls in over $4 billion.

Below, I'll tell you all about how investors are already cashing in on this incredible medical breakthrough — and how you can get in on the action as well.

But before I do that, let me tell you about the second part of the technology that is making this small biotech firm a key player in the vaccine industry.

The Man-Made Miracle of "Cell-Shock" Technology

"Cell-shock" technology is a delivery method that uses a small jolt of electricity to open the pores of the cells.

Normally, DNA molecules are too large to enter in the cell by themselves. This is a natural cellular defense to keep unwanted objects from entering.

But with the cell doors artificially stimulated, more of the genetic material in the vaccine is able to make it to a cell's replication center, increasing the number of antibodies the cell is able to produce.

This cell-shock technology is able to increase the uptake of DNA without the side effects normally associated with traditional vaccine types.

In other words, cell-shock technology is unmatched in its ability to safely, effectively, and economically deliver a genetically tailored vaccine to disease-ridden cells.

After 25 years and over $100 million in research, this overlooked micro-cap company has the dominant patent estate on this technology.

And if you move fast on their sub-$3.00 shares, you could be setting yourself up for the biggest payday of your life.

I'm not talking about banking a quick tenbagger on some minor advancement in treating some insignificant disease... I'm talking about the potential to rake in 100 to 1,000 times your money (or more) on prevention and curative technology that'll change the world of medicine forever.

But you must hurry if you expect to cash in...

Research universities and biotech companies across the globe are already using this company's cell-shock method to deliver genetic vaccines with astounding success.

One European company using this technology has already completed Phase I vaccine trials for Hepatitis C, the leading cause of chronic liver disease in the United States.

That's just one of several other research partners using this company's patented cell-shock technology.

And it doesn't end there, either...

This company has received over $25.1 million from the government and from various philanthropists and charities to develop a range of vaccines for everything from biodefense to diseases still running rampant in third world countries, like malaria.

With technology this revolutionary — and partners this big, it won't take much to push this company to the forefront of the vaccine revolution.

Below, I'll show you why it's crucial that investors get in on this action as soon as possible.

How to Make Record-Breaking Profits from a Record-Breaking Biotech

With a market cap under $460 million, our "Company X" is a David in a sea of Goliaths.

Just take a look at the market caps for this company and those of three Big Pharma companies:

Our firm is less than .25% the size of the smallest Big Pharma firm...

That's more than 400 times your money right there.

Think about it: Neither Novartis nor Roche has the patent on this revolutionary "cell-shock" technology. They couldn't cure and prevent cancer, HIV, influenza, or malaria even if they wanted to!

Plus, even for a mega-firm like Pfizer to produce even 100% gains, it has to effectively pull in over $153 billion — a practically impossible feat, even for a company with the research capabilities they have.

However, when you combine a market cap as small as that of our "Company X" with a miraculous medical technology on its way to curing the world's deadliest diseases, then even 10,000% gains would seem like a piece of cake.

Their ability to bring you ridiculous gains lies in their uniqueness: They're one of those rare companies that has been able to harness both a genetic vaccine and a delivery method that yields promising results for multiple diseases.

Instead of focusing on one specific virus or cell that causes one specific kind of cancer or disease, our little biotech start-up has been focusing on isolating the genes of several of mankind's biggest killers.

So while they're using the same vaccine technology for each disease, this technology is able to effectively fight any virus or cancer cell that has the potential to harm the human body.

The ability to produce multiple medical applications is key in an industry that is expected to push global revenues of...

More than $52 Billion in Annual Sales by 2016

And that's just the vaccine industry!

Already, other biotech companies are trying to ramp up production of vaccines that can treat and cure multiple conditions — cancer and the flu, for example.

But they'll fall utterly short of what this micro-biotech I'm telling you about today can accomplish.

Whereas most companies' vaccines are preventative measures, the kinds of genetic vaccines this firm specializes in are able to treat the disease even after infection has occurred.

You see, genetic vaccines fall under a broader category of therapeutic vaccines — vaccines that are able to produce antibodies that fight the intruding organism long after the virus or cancer has taken hold.

Take the human papilloma virus (HPV), for instance...

This virus causes genital warts. It's the major cause of cervical cancer among woman. HPV has managed to infect over 20 million women in the United States alone. It has also pushed cervical cancer to be the second deadliest cancer among women in the world.

While there is already a preventative vaccine out there for HPV, it does not help the women who are already infected — or the millions of others who remain undiagnosed...

Fortunately, our little biotech company has already started human testing on a genetic vaccine that can give hope to the millions of American women who are already suffering from HPV and cervical cancer.

But that's just the start for this little firm...

Preliminary animal tests of this company's "cell-shock" system have already shown 100% protection against the H1N1 version currently sweeping the globe!

This is why you must get in on this stock RIGHT NOW.

Even overcoming an obstacle as small as moving this vaccine into animal trials is enough to push this stock's gains well over 200%.

That's right: This stock has more than tripled in recent months on early word of what it can do.

The Vaccine that'll Turn Your $5,000 Investment into an Easy $500K Return

This company is on the verge of surpassing several major obstacles in the next couple of months:

1 vaccine program is already in the middle of Phase II human trials
6 vaccine programs are nearing the end of Phase I trials
2 vaccines were just sold to a major pharmaceutical company for $422 million
4 others are finishing up their preclinical trials

Every phase that one of these vaccines passes to is another good bump to this company's stock.

The further along the vaccine is, the more you can expect the stock to rise...

Completing any one of the human trials could easily see your gains reach triple digits — or more — especially when you consider that share prices for this stock are ridiculously low right now...

I'm talking under $3.00.

And while that is extremely good news to investors like you and me, it is becoming ultra-urgent that you get in on this stock as soon as possible...

News of this company's success in any of its trial phases could be easy triple-digit gains that you miss out on.

I'm going to tell you all about this biotech bonanza in our newest report. This report details the one company we've found that's on the edge of bringing the drug industry's "holy grail" to market: a single system for combating (and all but curing) the world's biggest killers.

I'll also tell you how this report can be yours absolutely FREE.

But before I go any further, let me tell you a bit more about myself...

The Opportunity is Staggering

My name is Christian DeHaemer.

I'm the Senior Investment Analyst for Angel Publishing, a financial research firm based in Baltimore, Maryland.

I'm also the founder of Technology and Opportunity, an investment advisory devoted to finding cutting-edge technology investments... investments that have the potential to double, triple, quadruple, and more.

If my name sounds familiar, it's probably because you've seen me making the rounds on the financial news circuit. In fact, I've been featured on numerous financial programs including Traders Nation, the Los Angeles Times, Forbes, CBS MarketWatch, Money Matters, Personal Finance Radio, and On the Money, to name a few.

With an extensive background in finance, I have over 15 years of hard-core Wall Street experience.

I've worked side by side with some of the most astute minds in the business. In fact, I've got a slew of hedge fund managers, pit traders, CIOs, Intel chip designers, and patent attorneys on my speed dial.

Make no mistake; the classified information they provide is priceless.

That usually means big money for my readers...

Just take a look at some of the winners I've uncovered:

759% on Petro Matad
690% Oracle
672% Sun Microsystems
498% on Simulations Plus
515% on Palm Source
558% on MBNA
411% on Africa Oil
302% on Aastrom Bioscience
362% on Evergreen Solar
278% on Summit Resources
129% on Sirius
162% on Markland Technologies
268% on China Yuchai
243% on CEMEX
148% on Railpower Tech (P.TO)
178% on Grupo Simec (SIM)
121% on Solidere
122% on Cannondale
147% on Bio Pham
192% on Holis Eden
118% on Take Two Interactive

Not bad. If you had put $10,000 in each of the above winners, you'd now be sitting on over $500,000.

And these gains are just the tip of the iceberg — a small fraction of the 350 winners I've nailed over my career.

As you can imagine, my readers are thrilled...

Take a look at what a few of them have called and written in to tell me:

"I'm up about $50,000 in one year on your recommendations. The subscription was itself the best investment I made last year, which was my best year of investing ever..." — Samuel S., Pennsylvania
"Up $21,600 in less than a week! Keep the very, very good recommendations coming!" — Cameron P., Kansas
"I've seen Chris in action before and he knows the business inside and out. It's hard to go wrong with his picks." — Ira G., California
"An absolute winner for me. In two days the price shot up like the sky is the limit. Thanks for the suggestion..." — Bernard L., South Africa

I've got a huge file full of testimonials just like these from delighted readers.

Bottom line: Folks are getting rich following my recommendations.

I hope you decide to join them today.

In order to help you get in early, I've put together a special report called, "The Vaccine of the Century."

And I'd like to send it to you today, free of charge, when you decide to give my Technology and Opportunity newsletter a risk-free try.

Let me tell you how to do that now...

Money Loves Speed!

Go ahead and give my newsletter, Technology and Opportunity, a risk-free try.

All you need do is click the "Join Us" button at the bottom of the page.

The moment I hear from you, you'll have immediate access to the special report "The Vaccine of the Century," featuring the biotech stock I've been telling you about...

The report will tell you everything you need to know to invest in this little-known company.

I can tell you right now that getting in on this stock would be like getting in early on Microsoft at the dawn of the computer revolution. Folks who had the vision to take action ended up multi-millionaires.

This is your chance to do the same.

That's because there is no better time to invest in technology, whether we are talking about pharmaceuticals or computers.

Think about it...

There's not a single sector of the economy that is not impacted by technology. From health care to consumer goods, technology is prevalent in every aspect of our daily lives.

Technology is just too hot to be ignored.

Even Warren Buffett, who is known for snubbing technology stocks, just took an $8 billion tech position!

Every day, new innovation hits the marketplace...

The ones that catch on can change the world — making early investors rich in the process.

I've already told you how biotech companies like Human Genome Sciences (HGS) made early investors 1,060%.

And let's not forget about companies like:

ACADIA Pharmaceuticals: 1,793% gain
China Biologic Products: 1,800% gain
Aegerion Pharmaceuticals: 685% gain
Biogen Idec: 7,677% gain

I could go on and on, but I think you get the idea...

When it comes to investing, technology is the place to be.

As a subscriber to Technology and Opportunity, you'll have a front-row seat to unfolding opportunities in this space.

Breakthrough Technology: A Fortune Just Waiting to Happen

Every day, scores of little-known companies speed toward creating things that were unimaginable even a few years ago.

Each month, I'll bring you a new company that is in the process of changing the world.

Most of these companies are unknown... but the impact they make can change the world — and create fortunes in the process.

Have a look at a few technology companies I've been watching recently:

Amgen Inc. (AMGN) provides human therapeutics for cancer care. They showed early investors gains of 108,000%.

LivePerson, Inc. (LPSN) provides live chat service for businesses. They showed early investors gains of 8,900%.

VirnetX Holding Corp. (VHC) provides Internet security. They showed early investors gains of 13,000%.

FLIR Systems (FLIR) provides thermal imaging technology. They showed early investors a 5,200% gain.

Stratasys (SSYS) provides 3D printing technology. They showed early investors a chance to pocket a 9,200% gain.

ANSYS (ANSS) provides simulation software technology. They showed early investors a 3,900% gain.

Bottom line: Breakthrough technology is a fortune just waiting to happen.

Of course, it's too late to get in on these home runs. They've already had their big run.

The good news is there are plenty more opportunities unfolding at this moment.

In fact, let me tell you about some breaking opportunities you'll learn about the moment you agree to give Technology and Opportunity a risk-free trial.

Keep in mind these are in addition to the special report, "The Vaccine of the Century"...

Bonus Report #1

"The 3 Biometric Technology Stocks for 2013 and Beyond!"
As you may know, biometrics identifies people through physical traits. I'm talking about voice recognition, fingerprint technology, face recognition, eye scanning, and more. The applications are limitless. For example, Apple has already integrated fingerprint sensing into its latest version of the iPhone. And get this: The company that's providing Apple with biometric technology recently soared 567%! The scope of biometrics is exploding, and I've identified three biometric stocks that could double, triple, or even quadruple or more in the coming months.

This report will show you why biometrics will transform the way companies do business. It will also show you exactly how to get in on these three companies at a fraction of their true value.

Bonus Report #2

"2 Drone Stocks to Own and 2 to Dump"
Drones used to be exclusively for military use. But in 2015, the Federal Aviation Administration will open the skies to commercial drones.

This is the birth of a whole new industry... and an opportunity for you to make a fortune.

In fact, I've isolated two drone stocks that are absolute home runs waiting to happen. Both of these companies are positioned for an explosive move upward. Right now, you have a chance to get in on the ground floor and reap enormous profits. This report will give you details on what each company is doing... how it's changing the world... and how you can cash in during the coming months.

In addition, I've included two drone stocks to stay away from, so that you can defend yourself from these riskier investments.

Both of these bonus reports are yours — absolutely free — the moment you agree to test-drive Technology and Opportunity.

Now, let me summarize everything you'll get as new subscriber:

12 Monthly Issues of Technology and Opportunity, jam-packed with new and exciting research on the hottest technology companies on the planet. Every month, I'll introduce you to a breakthrough company that has the potential to change the world. You'll get the name of the company, the stock symbol, and specific instructions that will help you invest for maximum profits.

Portfolio Updates – When pertinent, I'll send you a market pulse update letting you know what's happening in the world of technology. These updates will provide up-to-the-minute analysis of each of my recommendations.

Flash Alerts: Every day, I monitor the markets, keeping a close eye on each of my recommendations... If something changes with any of our positions, you'll be the first to know via my Flash Alerts.

Unlimited Access to Our Private Members-Only Website: Read back issues and new reports and stay up to date on the cutting-edge technology opportunities I uncover.

Plus, you'll get the reports I've outlined above:

Special Report: "The Vaccine of the Century"

Bonus Report #1: "The 3 Biometric Technology Stocks for 2013 and Beyond!"

Bonus Report #2: "2 Drone Stocks to Own and 2 to Dump"

Now you're probably wondering, How much does all this cost?

I'm pleased to tell you that's the best part...

Just 14 Cents per Day!

As you may know, investment research services can cost $1,000 or more per year.

In fact, I personally know people who pay well over $5,000 per year for seemingly the exact information you're going to get from Technology and Opportunity.

Now, Technology and Opportunity normally has an annual subscription fee of a very reasonable $129...

However, if you sign up within the next 24 hours, you'll lock in a special subscription fee of just $49 for a full year of Technology and Opportunity.

That means for about 14 cents a day, you'll get cutting-edge investment information that costs some people over $5,000!

I think you'll agree that's a flat-out bargain.

And because I want to make this a "no-brainer" for you, I'm going to go a step further to make sure you're absolutely comfortable trying Technology and Opportunity...

My Ironclad Guarantee

Here's my personal pledge: If at any time during the first 30 days you are unhappy with your Technology and Opportunity subscription — for any reason — just say the word...

I'll send you a check to cover every penny of your subscription expense — NO QUESTIONS ASKED!

And after the first 30 days, if you're not happy, I'll REFUND EVERY PENNY of the unused portion of your subscription — again, no questions asked!

And even if you decide to take a 100% refund, you can keep everything I send you, including the special report, "The Vaccine of the Century," and the bonus reports.

You have absolutely nothing to lose. And your upside on this opportunity is enormous.

But you must move quickly on this bio-pharma firm...

Word is getting out and already big institutional money is moving in. Things are going to move fast, and you need to get in position NOW to ensure full profit potential.

Remember: The people who had a chance to make 82,000% on Microsoft were the people with the vision to seize the opportunity early and get in on the ground floor.

So please, take just a moment to reserve your space by clicking the "Join Us" button below.

This opportunity won't wait, and I'd hate to see you miss out.

Sincerely,
Christian DeHaemer Signature

Christian DeHaemer
Founder, Technology and Opportunity
P.S. Remember, you have a full 30 days to try out Technology and Opportunity without risk or obligation. And even if you change your mind, you keep all three reports as my gift to you. You have absolutely nothing to lose... and your upside is virtually unlimited. Go ahead and Join Us Now.

Friday, January 24, 2014 8:01 AM

Hezbollah, Army on high alert in Beirut over bomb rumors

Lebanese forensic experts and Army soldiers inspect the site of a car bomb that targeted Beirut's southern suburb of Haret Hreik on January 03, 2014.

Hezbollah and the Lebanese Army have been on high alert after rumors circulated that two suicide bombers were planning to attack Beirut’s southern suburbs.

Unarmed Hezbollah members briefly erected checkpoints at several places along the Hadi Nasrallah highway in the southern suburbs Thursday, searching vehicles and examining drivers’ IDs.

The heightened security comes two days after a suspected suicide bomber killed four people and wounded scores of others in the southern suburb of Haret Hreik, where Hezbollah enjoys wide support.

The checkpoints were later removed, but traffic remained congested at the entrances to the southern suburbs, where the Army, Internal Security Forces and General Security have fixed checkpoints. They closely searched almost every passing car and checked the papers of both drivers and passengers.

Conversely, traffic was unusually light on Hadi Nasrallah highway and other parts of the southern suburbs.

“Honestly, I used to think that the Beirut southern suburbs were the safest place ever,” said Ali, a resident of Shiyah. “Nowadays, simply speaking, it seems to be the exact opposite.”

“When walking through the streets, I have a car bomb phobia, especially when I am walking across the highways. I get afraid passing by cars parked along the street,” he said. “I am [now] being more alert and watching out.”

Tuesday’s bombing in Haret Hreik was the fourth deadly blast targeting the southern suburbs. It came almost three weeks after a suicide attack struck the same street, killing six people. Car bombs also exploded in the city’s southern suburbs of Bir al-Abed and Ruwaiss last year, killing 30 people and wounding scores of others.

Rumors have often surfaced about rigged cars entering the suburbs and other parts of the country.

Residents of the southern suburbs circulated WhatsApp messages Thursday claiming that Hezbollah had asked residents not to pass through the area linking the Hadi Nasrallah highway to the Bir al-Abed neighborhood for three hours.

Hezbollah’s spokesperson could not be reached by The Daily Star to verify this information.

The party has previously denied sending such messages.

Many side roads leading to alleys in the southern suburbs were blocked with barricades, and plain-clothes young men, likely from Hezbollah, were seen standing on sidewalks.

Terrorist groups in Syria have claimed most of the attacks in the southern suburbs, describing them as retaliation for Hezbollah’s military involvement alongside President Bashar Assad’s troops in Syria.

The party announced last year that it joined the war in Syria to prevent the country from falling into the hands of Takfiri groups, a reference to the Syrian extremist militants.

Separately, the National News Agency said the Army thwarted an attempt by an armed group to sneak from Syria to Lebanon through illegal border crossings in the Masharih al-Qaa area in the Bekaa Valley.

Lebanese troops opened fire at the gunmen, forcing them to retreat, the NNA reported.

BA/BA

- See more at: http://en.alalam.ir/news/1558579#sthash.jzS6kgLg.dpuf